Impact of lactulose therapy on minimal hepatic encephalopathy and health-related quality of life in Ghanaian patients with cirrhosis.
Ghana Medical Journal · 2026 · 60 (2) · 54-61
DOI: 10.4314/gmj.v60i2.2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Ghana Medical Journal, 2026. Verfasst von Victoria A. Agyen-Frimpong und 4 weiteren Autor:innen.
Abstract (Originalsprache)
Objectives
To evaluate the impact of minimal hepatic encephalopathy (MHE) on health‑related quality of life (HRQoL) and to assess the association between lactulose therapy and changes in cognitive function and HRQoL in Ghanaian patients with liver cirrhosis.
Design
Prospective longitudinal observational pre–post study without a control group.
Setting
Gastroenterology clinic of Korle-Bu Teaching Hospital, Accra, GhanaParticipants: One hundred and thirty‑six adults (≥18 years) with liver cirrhosis who passed the Mini‑Mental State Examination were screened using the Psychometric Hepatic Encephalopathy Score (PHES). Seventy patients diagnosed with MHE were enrolled, and fifty‑eight completed the 12‑week follow‑up. Patients with overt hepatic enceph-alopathy, major neuropsychiatric disorders, or terminal illness were excluded.
Interventions
Patients with MHE received oral lactulose for 12 weeks, titrated to achieve 2–3 semisoft stools daily.Main outcome measures: Cognitive function assessed using PHES, and HRQoL measured with the Chronic Liver Disease Questionnaire (CLDQ).
Results
MHE was present in 51% of screened patients. At baseline, patients with MHE had lower total CLDQ scores than those without MHE (mean difference −9.3; 95% CI −17.3 to −1.3; p = 0.01). After 12 weeks of lactulose therapy, PHES performance and CLDQ scores improved among patients with MHE (p < 0.05 for all comparisons). Mild adverse effects occurred in 12.1%, with no treatment discontinuations.
Conclusions
MHE is common and associated with impaired HRQoL in patients with cirrhosis. Lactulose therapy was associated with improvements in cognitive function and HRQoL. Controlled studies are needed to confirm causality and assess long‑term outcomes, particularly in low‑resource settings.
Zitieren
APA
Agyen-Frimpong, V. A., Tachi, K., Agyei-Nkansah, A., Duah, A., & Mensah, M. (2026). Impact of lactulose therapy on minimal hepatic encephalopathy and health-related quality of life in Ghanaian patients with cirrhosis. Ghana Medical Journal, 60(2), 54-61. https://doi.org/10.4314/gmj.v60i2.2
Vancouver
Agyen-Frimpong VA, Tachi K, Agyei-Nkansah A, Duah A, Mensah M. Impact of lactulose therapy on minimal hepatic encephalopathy and health-related quality of life in Ghanaian patients with cirrhosis. Ghana Medical Journal. 2026;60(2):54-61. doi:10.4314/gmj.v60i2.2
BibTeX
@article{AgyenFrimpong2026,
author = {Agyen-Frimpong, Victoria A. and Tachi, Kenneth and Agyei-Nkansah, Adwoa and Duah, Amoako and Mensah, Michael},
title = {Impact of lactulose therapy on minimal hepatic encephalopathy and health-related quality of life in Ghanaian patients with cirrhosis},
journal = {Ghana Medical Journal},
year = {2026},
volume = {60},
number = {2},
pages = {54--61},
doi = {10.4314/gmj.v60i2.2}
}
EUVIMED